Decoding cancer therapy resistance through advanced 3D organoid systems
Year: 2026
Type: review
Abstract: Precision oncology still faces low clinical translation rates. This is largely because two-dimensional (2D) culture systems cannot reproduce tumor heterogeneity and microenvironmental stress. Here, we review the applications of 3D cancer models, including scaffold-free spheroids, patient-derived organoids (PDOs) biobanks, and microphysiological systems (MPSs), in drug resistance modeling and personalized therapy. These platforms effectively model metabolic gradients, lineage plasticity, and immunological features within the tumor microenvironment (TME), thereby bridging the genotype-phenotype gap. They also capture physical immune exclusion, T cell exhaustion, and antigen presentation to facilitate the evaluation of immunotherapies. Last, we discuss key translational bottlenecks such as standardization and throughput, proposing the integration of advanced biomanufacturing, artificial intelligence (AI)-driven phenomics, and computational modeling to develop 3D cancer platforms into clinical predictive systems for optimizing precision treatment strategies.
Source: Science Advances
Institutions: Sichuan University, State Key Laboratory of Oral Diseases, University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Hanzhong Central Hospital, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Keywords: cancer therapy resistance, 3D tumor models, patient-derived organoids, tumor spheroids, microphysiological systems, tumor microenvironment, precision oncology, immunotherapy evaluation, immune exclusion, T cell exhaustion, antigen presentation, tumor heterogeneity, bioproduction, computational modeling
Open Access status: gold
Estimated APC paid: $4,500
Award: G5160927543
OpenAlex ID: W7225992335
